AxSpA patients who also meet criteria for fibromyalgia: identifying distinct patient clusters using data from a UK national register (BSRBR-AS).
Axial spondyloarthritis
Cluster analysis
Comorbidity
Criteria
Disease register
Fibromyalgia
Journal
BMC rheumatology
ISSN: 2520-1026
Titre abrégé: BMC Rheumatol
Pays: England
ID NLM: 101738571
Informations de publication
Date de publication:
2019
2019
Historique:
received:
22
11
2018
accepted:
25
04
2019
entrez:
31
5
2019
pubmed:
31
5
2019
medline:
31
5
2019
Statut:
epublish
Résumé
Around 1 in 8 patients with axial spondyloarthritis (axSpA) also meet criteria for fibromyalgia and such patients have considerable unmet need. Identifying effective therapy is important but to what extent fibromyalgia-like symptoms relate to axSpA disease severity has not been established. The aim of the current analysis was to determine whether distinct clusters of axSpA patients exist and if so to determine a) whether they differ in terms of prevalence of fibromyalgia and b) the features of patients in clusters with high prevalence. The British Society for Rheumatology Biologics Register (BSRBR-AS) recruited axSpA patients from 83 centres 2012-2017. Clinical data, and information from patients was collected (including research criteria for fibromyalgia). Cluster analysis was undertaken using split samples for development and validation both in the whole population and the sub-group which met fibromyalgia criteria. One thousand three hundred thirty-eight participants were included of whom 23% met research criteria for fibromyalgia. Four clusters were identified. Two exhibited very high disease activity, one which was primarily axial ( The major feature defining clusters with a high proportion of persons meeting criteria for fibromyalgia is high axSpA disease activity although clusters with features of fibromyalgia in the absence of high disease activity also show moderately high prevalence. Management may be most successful with pharmacologic therapy to target inflammation but enhanced by the concurrent use of non-pharmacologic therapy in such patients.
Sections du résumé
BACKGROUND
BACKGROUND
Around 1 in 8 patients with axial spondyloarthritis (axSpA) also meet criteria for fibromyalgia and such patients have considerable unmet need. Identifying effective therapy is important but to what extent fibromyalgia-like symptoms relate to axSpA disease severity has not been established. The aim of the current analysis was to determine whether distinct clusters of axSpA patients exist and if so to determine a) whether they differ in terms of prevalence of fibromyalgia and b) the features of patients in clusters with high prevalence.
METHODS
METHODS
The British Society for Rheumatology Biologics Register (BSRBR-AS) recruited axSpA patients from 83 centres 2012-2017. Clinical data, and information from patients was collected (including research criteria for fibromyalgia). Cluster analysis was undertaken using split samples for development and validation both in the whole population and the sub-group which met fibromyalgia criteria.
RESULTS
RESULTS
One thousand three hundred thirty-eight participants were included of whom 23% met research criteria for fibromyalgia. Four clusters were identified. Two exhibited very high disease activity, one which was primarily axial (
CONCLUSIONS
CONCLUSIONS
The major feature defining clusters with a high proportion of persons meeting criteria for fibromyalgia is high axSpA disease activity although clusters with features of fibromyalgia in the absence of high disease activity also show moderately high prevalence. Management may be most successful with pharmacologic therapy to target inflammation but enhanced by the concurrent use of non-pharmacologic therapy in such patients.
Identifiants
pubmed: 31143851
doi: 10.1186/s41927-019-0066-7
pii: 66
pmc: PMC6532149
doi:
Types de publication
Journal Article
Langues
eng
Pagination
19Subventions
Organisme : Versus Arthritis
ID : 21378
Pays : United Kingdom
Déclaration de conflit d'intérêts
Competing interestsThe authors declare that they have no competing interests.
Références
Ann Rheum Dis. 2003 Jan;62(1):20-6
pubmed: 12480664
Nat Clin Pract Rheumatol. 2006 Feb;2(2):90-8
pubmed: 16932662
Ann Rheum Dis. 2009 Jun;68(6):777-83
pubmed: 19297344
Rheumatology (Oxford). 2010 Apr;49(4):812-9
pubmed: 20100797
J Rheumatol. 2010 Oct;37(10):1991-2005
pubmed: 20682676
Ann Rheum Dis. 2011 Jan;70(1):47-53
pubmed: 21068095
J Rheumatol. 2011 Jun;38(6):1113-22
pubmed: 21285161
Arthritis Rheumatol. 2015 Feb;67(2):568-75
pubmed: 25323744
Ann Intern Med. 2015 Aug 4;163(3):191-204
pubmed: 26054060
BMC Musculoskelet Disord. 2015 Nov 11;16:347
pubmed: 26559487
Arthritis Res Ther. 2016 Feb 09;18:42
pubmed: 26860612
J Rheumatol. 2016 Nov;43(11):2056-2063
pubmed: 27633820
Semin Arthritis Rheum. 2016 Dec;46(3):319-329
pubmed: 27916278
Arthritis Rheumatol. 2017 Nov;69(11):2144-2150
pubmed: 28622461
Arthritis Rheumatol. 2018 Jul;70(7):1000-1007
pubmed: 29439291
Rheumatology (Oxford). 2018 Jun 1;57(6):987-996
pubmed: 29529295
Rheumatology (Oxford). 2018 Aug 1;57(8):1453-1460
pubmed: 29788461
Nat Commun. 2018 Jun 8;9(1):2243
pubmed: 29884867
Rheumatology (Oxford). 2018 Nov 1;57(11):1982-1990
pubmed: 30053166
Front Med (Lausanne). 2018 Oct 24;5:290
pubmed: 30406105
J Clin Epidemiol. 1988;41(4):313-21
pubmed: 3351539
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
J Rheumatol. 1994 Dec;21(12):2281-5
pubmed: 7699629
J Rheumatol. 1994 Dec;21(12):2286-91
pubmed: 7699630
J Rheumatol. 1994 Sep;21(9):1694-8
pubmed: 7799351
J Psychosom Res. 1993;37(2):147-53
pubmed: 8463991
Br J Rheumatol. 1996 Jan;35(1):66-71
pubmed: 8624626
Med Care. 1996 Mar;34(3):220-33
pubmed: 8628042